Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Human Clinical Trial Shows Stem Cell Therapy Hastens Bone Repair

By BiotechDaily International staff writers
Posted on 11 Jul 2013
Treatment of fractures of the pelvic bones with stem cells halved recovery time in a clinical study conducted over the past four years.

Investigators at the Hadassah Medical Organization (Jerusalem, Israel) worked with a group of 24 patients with severe pelvis fractures. Breaks of this kind are especially slow to heal due to the scant layer of muscle and bone support tissue present as well as reduced blood supply.

The protocol used in this study called for 50 milliliters of bone marrow and 100 milliliters of blood to be extracted from the patient's pelvic area. Mesenchymal stem cells were isolated from the bone marrow, and an enriched platelet fraction was prepared from the blood. The stem cells and enriched platelet fraction were mixed with demineralized bone matrix (DBM) and injected under fluoroscopic control into the fracture site. A control group did not receive stem cells.

Results published in the June 4, 2013, online edition of the journal Molecular Therapy revealed that the stem cell therapy was a safe and efficient procedure, as no complications occurred in either group. The median time for bone repair was 1.5 months in the stem cell treated group and three months in the control group.

First author Dr. Meir Liebergall, professor of orthopedic surgery at the Hadassah Medical Organization, said, “A process that began 15 years ago eventually led to this clinical trial at Hadassah, the first of its kind in Israel. The trial included 24 patients with severe pelvis fractures. This research is a medical breakthrough. Publication of this study and its findings will most likely change the currently accepted principles of treating complicated fractures. Now, we face the challenge of understanding this healing mechanism and how it works.”

Related Links:

Hadassah Medical Organization




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.